GlassScriptPhysician profile
Ashish Sharma
NPI 1699066613
$1,698.88
in general payments reported to CMS, 2019-2025
21 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $42.76 · 2021: $159 · 2022: $90.86 · 2023: $462 · 2024: $410 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $469.40 | 2022-2025 | Skyrizi, Mavyret, Rinvoq |
| Janssen Biotech, INC. | $193.02 | 2021-2024 | Stelara, Tremfya |
| Celgene Corporation | $151.44 | 2023-2024 | Zeposia |
| Boston Scientific Corporation | $141.72 | 2019 | |
| Novo Nordisk INC | $134.97 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $83.72 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $70.02 | 2023-2025 | Entyvio, Gattex |
| Janssen Scientific Affairs, LLC | $62.57 | 2025 | |
| Lilly USA, LLC | $52.92 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $47.95 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.42 | 2020-2024 | Xifaxan |
| Pfizer INC. | $37.73 | 2020-2023 | |
| Genzyme Corporation | $32.71 | 2022 | |
| Amgen INC. | $28.11 | 2023 | Avsola, Amjevita |
| Gilead Sciences, INC. | $27.70 | 2019-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24.85 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $23.47 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $21.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.02 | 2023 | |
| Braintree Laboratories, INC. | $14.79 | 2024 | Suflave |
| Phathom Pharmaceuticals, INC. | $11.45 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.